D.E. Shaw & Co
GENB

D.E. Shaw & Co’s Generate Biomedicines GENB Stock Holding History

D.E. Shaw & Co’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.19M Buy
+95,000
New +$1.16M ﹤0.01% 3319

Other funds holding GENB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

D.E. Shaw & Co's GENB Position: Q1 2026 in Review

D.E. Shaw & Co opened a new position in Generate Biomedicines (GENB) in Q1 2026: 95,000 shares worth $1.19M. The stake represents ﹤0.01% of the portfolio and ranks #3319 among its holdings.

57 funds tracked by Wall St. Rank hold GENB as of Q1 2026.

  • D.E. Shaw & Co held 95,000 shares of Generate Biomedicines worth $1.19M as of Q1 2026.
  • Generate Biomedicines was a new D.E. Shaw & Co position in Q1 2026.
  • Generate Biomedicines made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #3319 holding.
  • 57 funds tracked by Wall St. Rank held Generate Biomedicines as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.